SR146131: A new potent, orally active, and selective nonpeptide cholecystokinin subtype 1 receptor agonist. I: In vitro studies

Journal of Pharmacology and Experimental Therapeutics

Volumn 289, Issue 2, 1999, Pages 742-751

  Bignon, Eric ^a   Bachy, André ^a   Boigegrain, Robert ^a   Brodin, Roger ^a   Cottineau, Michèle ^a   Gully, Danielle ^a   Herbert, Jean Marc ^a   Keane, Peter ^a   Labie, Christophe ^a   Molimard, Jean Charles ^a   Olliero, Dominique ^a   Oury Donat, Florence ^a   Petereau, Christophe ^a   Prabonnaud, Valérie ^a   Rockstroh, Marie Pierre ^a   Schaeffer, Paul ^a   Servant, Orlane ^a   Thurneyssen, Olivier ^a   Soubrié, Philippe ^a   Pascal, Marc ^a   Maffrand, Jean Pierre ^a   Le Fur, Gerard ^a   more..

^a SANOFI   (France)

Author keywords

[No Author keywords available]

Indexed keywords

1 (2,3 DIHYDRO 1 METHYL 2 OXO 5 PHENYL 1H 1,4 BENZODIAZEPIN 3 YL) 3 (3 METHYLPHENYL)UREA; 2 [4 (4 CHLORO 2,5 DIMETHOXYPHENYL) 5 (2 CYCLOHEXYLETHYL) THIAZOL 2 YLCARBAMOYL] 5,7 DIMETHYL INDOL 1 YL 1 ACETIC ACID; 4 [[2 [2 [[(2 ADAMANTYLOXY)CARBONYL]AMINO] 3 (1H INDOL 3 YL) 2 METHYLPROPIONAMIDO] 1 PHENYLETHYL]AMINO] 4 OXOBUTYRIC ACID MEGLUMINE; CALCIUM; CHOLECYSTOKININ OCTAPEPTIDE; CHOLECYSTOKININ RECEPTOR BLOCKING AGENT; DEVAZEPIDE; INOSITOL PHOSPHATE; LINTITRIPT; MITOGEN ACTIVATED PROTEIN KINASE; SR 146131; UNCLASSIFIED DRUG;

ANIMAL CELL; CALCIUM TRANSPORT; CELL LINE; CONFERENCE PAPER; DRUG EFFECT; DRUG RECEPTOR BINDING; DRUG SELECTIVITY; DRUG STRUCTURE; ENZYME ACTIVATION; GENE EXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; NONHUMAN; PRIORITY JOURNAL;

3T3 CELLS; ANIMALS; CA(2+)-CALMODULIN DEPENDENT PROTEIN KINASE; CALCIUM; CHO CELLS; CRICETINAE; DEVAZEPIDE; DNA-BINDING PROTEINS; EARLY GROWTH RESPONSE PROTEIN 1; GENES, IMMEDIATE-EARLY; HORMONE ANTAGONISTS; HUMANS; IMMEDIATE-EARLY PROTEINS; INDOLEACETIC ACIDS; INDOLES; INOSINE MONOPHOSPHATE; MICE; NEUROBLASTOMA; RECEPTOR, CHOLECYSTOKININ A; RECEPTOR, CHOLECYSTOKININ B; RECEPTORS, CHOLECYSTOKININ; RECOMBINANT PROTEINS; SINCALIDE; THIAZOLES; TRANSCRIPTION FACTORS; TUMOR CELLS, CULTURED;

EID: 0032902557     PISSN: 00223565     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Conference Paper

References (40)

1. Asin KE and Bednarz L (1992) Differential effects of CCK-JMV-180 on food intake in rats and mice. Pharmacol Biochem Behav 42:291-295.
2. Barrett RW, Steffey ME and Wolfram CAW (1989) Type-A cholecystokinin receptors in CHP212 neuroblastoma cells: Evidence for association with G protein and activation of phosphoinositide hydrolysis. Mol Pharmacol 35:394-400.
3. Berridge MJ (1983) Rapid accumulation of inositol trisphosphate reveals that agonists hydrolyse polyphosphoinositides instead of phosphatidylinositol. J Biochem (Tokyo) 212:849-858.
4. Bianchi BR, Miller TR, Witte DG and Lin CW (1994) Novel CCK analogues and bombesin: A detailed analysis between phosphoinositide breakdown and high-dose inhibition of pancreatic enzyme secretion in three rodent species. J Pharmacol Exp Ther 268:996-1002.
5. Bouaboula M, Poinot-Chazel C, Bourrié B, Canat X, Calandra B, Rinaldi-Carmona M, Le Fur G and Casellas P (1995) Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem J 312:637-641.
6. Chang RSL and Lotti VJ (1986) Biochemical and pharmacological characterization of an extremely potent and selective nonpeptide cholecystokinin antagonist. Proc Natl Acad Sci USA 83:4923-4926.
7. Crawley JN and Corwin RL (1994) Biological actions of cholecystokinin. Peptides 16:731-755.
8. Dabrowski A, Grady T, Logsdon CD and Williams JA (1996) Jun kinases are rapidly activated by cholecystokinin in rat pancreas both vitro and in vivo. J Biol Chem 271:5686-5690.
9. Dabrowski A, Detjen KM, Logsdon CD and Williams JA (1997) Stimulation of both CCK-A and CCK-B receptors activates MAP kinases in AR42J and receptor-transfected CHO cells. Digestion 58:361-367.
10. Day HEW, McKnight AT, Poat JA and Hughes J (1994) Evidence that cholecystokinin induces immediate early gene expression in the brainstem, hypothalamus and amygdala of the rat by a CCKA receptor mechanism. Neuropharmacology 33:719-727.
11. +. Biochem Biophys Res Commun 194:811-818.
12. Duan RD and Williams JA (1994) Cholecystokinin rapidly activates mitogen-activated protein kinase in rat pancreatic acini. Am J Physiol 267:G401-G408.
13. Dunlop J, Zhang Y and Evans N (1997) Full and partial agonist activity of C-terminal cholecystokinin peptides at the cloned human CCK-A receptor expressed in Chinese hamster ovary cells. Peptides 18:865-868.
14. Galas MC, Lignon MF, Rodriguez M, Mendre C, Fulcrand P, Laur J and Martinez J (1988) Structure-activity relationship studies on cholecystokinin: Analogues with partial agonist activity. Am J Physiol 254:G176-G182.
15. Grynkiewicz G, Poenie M and Tsien RJ (1985) A new generation of calcium indicators with greatly improved fluorescence properties. J Biol Chem 260:3440-3450.
16. Gully D, Frehel D, Marcy C, Spinazze A, Lespy L, Neliat G, Maffrand JP and Le Fur G (1993) Peripheral biological activity of SR27897: A new potent non-peptide antagonist of CCKA receptors. Eur J Pharmacol 232:13-19.
17. Henke BR, Aquino CJ, Birkemo LS, Croom DK, Dougherty RW Jr, Ervin GN, Grizzle MK, Hirst GC, James MK, Johnson MF, Queen KL, Sherrill RG, Sugg EE, Suh EM, Szewczyk JW, Unwalla RJ, Yingling J and Willson TM (1997) Optimization of 3-(1H-Indazol-3-ylmethyl)-1,5-benzodiazepines as potent, orally active CCK-A agonists. J Med Chem 40:2706-2725.
18. Holladay MW and Lin CW (1992) CCK agonists: A summary of structure-activity relationships with a focus on A-71378, a potent selective CCK-A agonist. Drug Future 17:197-206.
19. Hughes J, Boden P, Costall B, Domeney A, Kelly E, Horwell DC, Hunter JC, Pinnock RD and Woodruff GN (1990) Development of a class of selective cholecystokinin type B receptor antagonists having potent anxiolytic activity. Proc Natl Acad Sci USA 87:6728-6732.
20. Kissileff HR, Pi-Sunyer FX, Thornton J and Smith GP (1981) C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 34:154-160.
21. Lee YM, Beinborn M, McBride EW, Lu M, Kolakouski LF Jr and Kopin AS (1993) The human brain cholecystokinin-B/gastrin receptor. Cloning and characterization. J Biol Chem 268:8164-8169.
22. Lieverse RJ, Jansen JBMJ, Masclee AAM and Lamers CBHW (1994) Role of cholecystokinin in the regulation of satiation and satiety in humans. Ann NY Acad Sci 713:268-272.
23. Lin CW, Holladay MW, Witte DG, Miller TR, Wolfram CAW, Bianchi BR, Bennett MJ and Nadzan AM (1990) A-71378: A CCK agonist with high potency and selectivity for CCK-A receptors. Am J Physiol 258:G648-G651.
24. Lin CW, Shiosaki K, Miller TR, Witte DG, Bianchi BR, Wolfram CAW, Kopecka H, Craig R, Wagenaar F and Nadzan AM (1991) Characterization of two novel cholecystokinin tetrapeptide (30-33) analogues, A-71623 and A-70874, that exhibit high potency and selectivity for cholecystokinin-A receptors. Mol Pharmacol 39:346-351.
25. Lotti VJ and Chang RSL (1989) A new potent and selective non-peptide gastrin antagonist and brain cholecystokinin receptor (CCK-B) ligand: L-365,260. Eur J Pharmacol 162:273-280.
26. Lu L and Logsdon CD (1992) CCK, bombesin, and carbachol stimulate c-fos, c-jun, and c-myc oncogene expression in rat pancreatic acini. Am J Physiol 263:G327-G332.
27. Matozaki T, Martinez J and Williams JA (1989) A new CCK analogue differrentiates two functionally distinct CCK receptors in rat and mouse pancreatic acini. Am J Physiol 257:G594-G600.
28. 2+ mobilization and phospholipid hydrolysis in isolated rat pancreatic acini. J Biol Chem 266:6247-6254.
29. Munson PJ and Rodbard D (1980) Ligand: A versatile computerized approach for characterization of ligand-binding systems. Anal Biochem 107:220-239.
30. Ratkovsky DA and Reedy TJ (1986) Choosing near-linear parameters in the four parameters logistic model radioligands and related assays. Biometrics 42:575-582.
31. Saito A, Goldfine ID and Williams JA (1981) Characterization of receptors for cholecystokinin and related peptides in mouse cerebral cortex. J Neurochem 37: 483-490.
32. Schaeffer P, Prabonnaud V, Roux M, Gully D and Herbert JM (1994) CCK-JMV-180 acts as an antagonist of the CCKA receptor in the human IMR-32 neuroblastoma cell line. Febs Lett 354:203-206.
33. Simmons RD, Kaiser FC, Pierson ME and Rosamond JR (1998) ARL15849: A selective CCK-A agonist with anorectic activity in the rat and dog. Pharmacol Biochem Behav 59:439-444.
34. Stark HA, Sharp CM, Sutliff VE, Martinez J, Jensen RT and Gardner JD (1989) CCK-JMV-180: A peptide that distinguishes high-affinity cholecystokinin receptors from low-affinity cholecystokinin receptors. Biochim Biophys Acta 1010:145-150.
35. Steigerwalt RW and Williams JA (1981) Characterization of cholecystokinin receptors on rat pancreatic membranes. Endocrinology 109:1746-1753.
36. Tateishi K, Funakoshi A, Misumi Y and Matsuoka Y (1998) Jun and MAP kinases are activated by cholecystokinin in the pancreatic carcinoma cell line KP-1N. Pancreas 16:499-504.
37. Ulrich CD, Ferber I, Holicky E, Hadac E, Buell G and Miller LJ (1993) Molecular cloning and functional expression of the human gallbladder cholecystokinin A receptor. Biochem Biophys Res Commun 193:204-211.
38. Wank SA (1998) G Protein-coupled receptors in gastrointestinal physiology I. CCK receptors: An exemplary family. Am J Physiol 274:G607-G613.
39. Wank SA, Pisegna JR and de Weerth A (1994) Cholecystokinin receptor family. Molecular cloning, structure, and functional expression in rat, guinea pig and human. Ann NY Acad Sci 713:49-66.
40. Yule DI, Tseng MJ, Williams JA and Logsdon CD (1993) A cloned CCK-A receptor transduces multiple signals in response to full and partial agonists. Am J Physiol 265:G999-G1004.